Skip to main content

Table 1 Uni- and multivariate Cox regression analyses for OS including the four molecular classifications

From: Validation and comparison of the molecular classifications of pancreatic carcinomas

Characteristics Univariate Multivariate** w/ Moffitt tumor Multivariate** w/ Moffitt stroma Multivariate** w/ Collisson Multivariate** w/ Bailey Multivariate** w/ four classifications
N HR [95CI] P* N HR[95CI] P* N HR[95CI] P* N HR[95CI] P* N HR[95CI] P* N HR[95CI] P*
Age at diagnosis >60 vs. ≤60 years 364 1.21 [0.89–1.65] 0.233                
Sex male vs. female 367 1.13 [0.85–1.50] 0.392                
AJCC Stage 2 vs. 1 515 2.36 [1.56–3.58] 2.16E-04 215 1.52[0.24–9.63] 0.658 209 0.56[0.1–3.32] 0.527 215 0.64 [0.1–4.01] 0.632 215 0.97 [0.14–6.62] 0.979    
3 vs. 1   3.54 [1.53–8.22]   215 24.42[1.46–408] 2.61E-02 209 <NA>[NA-NA] <NA> 215 13.58[0.83–222.5] 0.067 215 19.9[1.15–345.4] 0.040    
4 vs. 1   3.56 [1.53–8.30]   215 0.00[0.00-Inf] 0.999 209 0.00[0.00-Inf] 0.999 215 0 [0-Inf] 0.998 215 0 [0-Inf] 0.999    
Pathological type other vs. ductal 548 0.14 [0.03–0.55] 5.27E-03 215 0.00[0.00-Inf] 0.996 209 0.00[0.00-Inf] 0.996 215 0 [0-Inf] 0.996 215 0 [0-Inf] 0.996    
Pathological grade 2 vs. 1 280 2.67 [1.15–6.21] 3.14E-03 215 1.34[0.55–3.25] 0.521 209 1.08[0.44–2.69] 0.862 215 1.39 [0.57–3.38] 0.470 215 1.31 [0.54–3.2] 0.556    
3 vs. 1   4.19 [1.79–9.81]   215 1.71[0.7–4.18] 0.242 209 1.29[0.53–3.18] 0.574 215 1.55 [0.64–3.79] 0.332 215 1.47 [0.6–3.58] 0.400    
4 vs. 1   4.78 [0.96–23.8]   215 3.25[0.36–29.4] 0.295 209 3.66[0.4–33.48] 0.251 215 6.62 [0.61–71.8] 0.120 215 3.27 [0.35–30.11] 0.296    
pT 2 vs. 1 393 1.81 [0.75–4.36] 1.85E-02 215 2.03[0.23–17.9] 0.524 209 2.28[0.26–20.18] 0.460 215 3.37 [0.37–30.38] 0.280 215 1.75 [0.19–16.17] 0.623    
3 vs. 1   2.64 [1.16–5.98]   215 2.74[0.19–38.8] 0.456 209 4.61[0.33–63.47] 0.254 215 5.66 [0.39–81.41] 0.203 215 3.33 [0.22–51.1] 0.389    
4 vs. 1   3.90 [1.35–11.2]   215 <NA>[NA-NA] <NA> 209 <NA>[NA-NA] <NA> 215 <NA> [NA-NA] <NA> 215 <NA> [NA-NA] <NA>    
pN 1 vs. 0 451 2.01 [1.5–2.7] 2.86E-06 215 1.37[0.78–2.39] 0.270 209 1.42[0.81–2.5] 0.219 215 1.62 [0.93–2.84] 0.090 215 1.4 [0.78–2.54] 0.261    
Moffitt “tumor” classical vs.
basal-like
601 0.59 [0.48–0.73] 1.17E-06 215 0.43[0.26–0.73] 1.56E-03           574 0.91[0.67–1.24] 0.557
Moffitt “stroma” normal vs. activated 574 0.64 [0.51–0.8] 8.46E-05     209 0.56[0.32–0.98] 4.25E-02        574 0.73[0.57–0.92] 9.07E-03
Collisson exocrine-like vs. classical 601 0.90 [0.71–1.15] 1.79E-03        215 0.74 [0.44–1.25] 0.266     574 0.96[0.68–1.35] 0.801
quasi-mesenchymal vs. classical   1.47 [1.13–1.91]         215 0.75 [0.29–1.95] 0.561     574 0.92[0.66–1.28] 0.615
Bailey immunogenic vs. ADEX 601 1.00 [0.70–1.42] 1.03E-07           215 0.98 [0.43–2.24] 0.961 574 0.93[0.59–1.47] 0.759
pancreatic progenitor vs. ADEX   1.13 [0.82–1.57]            215 1.64 [0.78–3.45] 0.196 574 1.06[0.69–1.63] 0.777
squamous vs. *ADEX   1.99 [1.50–2.65]            215 2.3 [1.16–4.55] 1.69E-02 574 1.69[1.09–2.62] 1.94E-02
  1. *P-value for Wald test; **the multivariate analysis included all variables significant (p < =0,05) in univariate analysis; pT, pathological tumor size (pT); pN, pathological lymph node status. The P-values in boldface and italicized represent the significant P-values